Method Of Storing Cells In A Viable State Patents (Class 435/374)
  • Publication number: 20130189723
    Abstract: The present invention relates generally to the field of cell culture, which is a laboratory process used primarily for the growth, propagation, and production of cells for analysis and the production and harvesting of cell products. The present invention comprises functionalized and/or engineered hydrogel microcarriers that exhibit any or all of the following properties: controllable buoyancy, ferro- or paramagnetism, molecular or fabricated reporting elements, and optical clarity. The microcarriers are used in a bioreactor that employs external forces to control said microcarrier kinetic energy and translational or positional orientation in order to facilitate cell growth and/or cellular analysis. The bioreactor can be part of an automated system that employs any or all of the following; a microcarrier manufacturing method, a monitoring method, a cell culture method, and an analytical method.
    Type: Application
    Filed: September 26, 2012
    Publication date: July 25, 2013
    Applicant: Global Cell Solutions, LLC
    Inventor: Global Cell Solutions, LLC
  • Publication number: 20130183343
    Abstract: The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells.
    Type: Application
    Filed: March 15, 2011
    Publication date: July 18, 2013
    Inventors: Brian J. Czerniecki, Shuwen Xu, Gary K. Koski, Brian McDevitt
  • Publication number: 20130183273
    Abstract: Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided.
    Type: Application
    Filed: January 29, 2013
    Publication date: July 18, 2013
    Applicant: Auxocell Laboratories, Inc.
    Inventor: Auxocell Laboratories, Inc.
  • Publication number: 20130183656
    Abstract: The present invention relates to compositions and methods for the handling of processed sperm including samples that are freshly collected, those transported as fresh samples, samples that are frozen and thawed, those sorted into one or more subpopulations, and those that are otherwise processed or handled that impose trauma on the cell. Trauma can reduce the motility, fertility, viability and overall integrity of the sperm and reduce the ability to fertilize, produce an embryo and a healthy offspring. The present invention relates to novel compounds that can be added to the sperm cell sample to reduce the traumatic effects of physical stress during mild as well as extensive sperm cell processing, methods of using the compounds in standard sperm processing procedures, the end products made from these methods including sperm and embryos, as well as methods of using those end products in assisted reproductive biology techniques in animals.
    Type: Application
    Filed: June 1, 2012
    Publication date: July 18, 2013
    Applicant: INGURAN, LLC
    Inventors: Richard Lenz, Juan Moreno, Ramakrishnan Vishwanath
  • Publication number: 20130183661
    Abstract: A method of producing extremely stable leukocytes from human blood samples which are stable for long period of time under extraordinary temperature conditions. The method also relates to producing and stabilizing the leukocytes with formaldehyde release agents. The method is directed at the use of the stabilized leukocytes as a control in assays for determining CD4+ and HIV diagnosis and therapy.
    Type: Application
    Filed: September 13, 2011
    Publication date: July 18, 2013
    Applicant: HERZ-UND DIABETESZENTRUM NORDRHEIN-WESFALEN KRANKENHAUSBETRIEBSGESELLSCHAFT BAD OEYNHAUSEN MBH
    Inventors: Christian Prante, Knut Kleesiek, Wolfgang Prohaska
  • Patent number: 8486696
    Abstract: Substantially homogenous cells populations which co-express CD49c, CD90 and telomerase are made. In one embodiment, humans suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition are treated with the substantially homogenous cells populations which co-express CD49c, CD90 and telomerase. In another embodiment, committed progenitor cells are made are made by selecting from a cultured source of a cell population which co-express CD49c and CD90 and modifying the cell population. The committed progenitor cells can be employed to treat a human suffering from a degenerative, traumatic, acute injury, cardiac or neurological condition and formulate pharmaceutical compositions.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: July 16, 2013
    Assignee: Garnet BioTherapeutics, Inc.
    Inventors: Tony W. Ho, Gene C. Kopen, William F. Righter, J. Lynn Rutkowski, Joseph Wagner
  • Publication number: 20130171613
    Abstract: Flush preservation solution for the preservation of cells in the absence of a blood supply comprising: v) water for injection; and vi) at least one saccharide such as a monosaccharide, disaccharide, trisaccharide, or polysaccharide and vii) at least one component with pH buffer properties; and viii) at least one component with calcium transport blocking properties or an anti-calcium action activity; method for the preparation thereof; use thereof in transplantation including organs from heart beating or non heart beating donors, in surgery including any situation of warm or cold ischaemia, cardioplegia or open heart surgery, whole limb or whole body preservation in experimentation on living tissues or in culturing and preserving engineered cells, tissues and organs, limbs or the whole body; method for flushing, preserving or flush preservation of cells; and a kit of parts comprising the solution components.
    Type: Application
    Filed: June 29, 2012
    Publication date: July 4, 2013
    Inventors: David Potts, Jeremy Peter Alan Lodge
  • Publication number: 20130171180
    Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt thereof, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportion, in particular a mixture of enantiomers, and particularly a racemate mixture, as well as to their process of preparation, their use in the peptide synthesis, said peptide and the use of said peptide.
    Type: Application
    Filed: December 22, 2011
    Publication date: July 4, 2013
    Applicant: TFCHEM
    Inventors: Geraldine Deliencourt-Godefroy, Hyacinthe Fillon, Thibaut Martin
  • Patent number: 8476071
    Abstract: The present invention relates to methods for expanding a stem cell population. More particularly, the invention relates, inter alia, to methods and compositions for expanding a stem cell population, particularly a hematopoietic stem cell population.
    Type: Grant
    Filed: August 9, 2012
    Date of Patent: July 2, 2013
    Assignee: Stowers Institute for Medical Research
    Inventors: John M. Perry, Linheng Li, Justin C. Grindley
  • Publication number: 20130157362
    Abstract: A method of liquid nitrogen surface vitrification requiring an embryo washed in a rinsing medium, then incubated in a base medium and incubated in a hold medium before being washed in a vitrification medium and produced into a vitrification droplet (270). For forming the droplet, vitrification medium (210), an intermediary fluid such as air, followed by vitrification medium containing at least one embryo (250) are aspirated into the channel. The vitrification droplet consequently can contain an air bubble (220). The vitrification droplet can be produced from an instrument with a channel and dropped directly into liquid phase nitrogen producing a vitrified droplet. The vitrified droplet can be stored in cryo-vessels, and warmed for revitalization of biological function of vitrified biological cell mass or tissues, such as oocytes and/or embryos.
    Type: Application
    Filed: August 17, 2011
    Publication date: June 20, 2013
    Applicant: INGURAN, LLC
    Inventors: Fuliang Du, Jie Xu, Juan Moreno
  • Publication number: 20130158341
    Abstract: Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cell characteristics, such as viability, motility, functionality, fertilization rates, and pregnancy rates. Further, sperm cell characteristics may be addressed within the context of various collection, handling, separation, storage, transportation, usage, fertilization, or insemination techniques.
    Type: Application
    Filed: February 12, 2013
    Publication date: June 20, 2013
    Applicant: XY, LLC
    Inventor: XY, LLC
  • Patent number: 8460926
    Abstract: To provide an aqueous solution for cell preservation which is free of a natural animal-derived component such as a basal medium or serum. An aqueous preservation solution showing a high cell survival rate was obtained by removing a natural animal-derived component such as a basal medium or serum and controlling other components and their concentrations.
    Type: Grant
    Filed: November 17, 2006
    Date of Patent: June 11, 2013
    Assignee: Nippon Zenyaku Kogyo Co., Ltd
    Inventors: Naoto Yamashiro, Kohichi Saze, Osamu Ohneda, Masumi Nagano
  • Publication number: 20130137094
    Abstract: The invention relates to a one-step chemical composition that preserves animal tissue, cells, and biomolecules, such as human tissue, human cells, and biomolecules therein. It improves the fidelity and morphologic structure of cells, organelles, and nuclear chromatin, and maintains and enhances the cellular antigenicity for immunohistochemistry and flow cytometry, while preserving proteins, post-translational modifications of proteins, and nucleic acids. In one embodiment, the composition comprises a) a non-aldehyde precipitating fixative at a concentration below 25% (volume/volume), b) a reversible/cleavable protein cross-linker that targets lipid-associated molecules, and c) a c reversible/cleavable protein cross-linker that targets water soluble molecules. In another embodiment, the composition further includes a kinase inhibitor, a phosphatase inhibitor, and a permeation enhancer.
    Type: Application
    Filed: January 25, 2011
    Publication date: May 30, 2013
    Applicant: GEORGE MASON INTELLECTUAL PROPERTIES, INC.
    Inventors: Virginia A. Espina, Lance A. Liotta, Claudius Mueller
  • Patent number: 8449902
    Abstract: This invention relates to the production of biomaterials with variable stiffness by subjecting a gel which varies in at least one dimension to plastic compaction. These biomaterials may be useful, for example, for the directional control or guidance of cells within tissue equivalent implants.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: May 28, 2013
    Assignee: UCL Business PLC
    Inventors: Robert Brown, Ektors Hadjipanayi
  • Patent number: 8445277
    Abstract: Certain embodiments disclosed herein include, but are not limited to, at least one of compositions, methods, devices, systems, kits, or products regarding rejuvenation or preservation of germ cells or gametes. Certain embodiments disclosed herein include, but are not limited to, methods of modifying germ cells or gametes, or methods of administering modified germ cells or gametes to at least one biological tissue.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: May 21, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Roderick A. Hyde, Edward K. Y. Jung, Lowell L. Wood, Jr.
  • Publication number: 20130121972
    Abstract: Noncultured Wharton's Jelly stem cells and methods of their purification, storage and use are provided.
    Type: Application
    Filed: June 1, 2011
    Publication date: May 16, 2013
    Inventor: Rouzbeh R. Taghizadeh
  • Patent number: 8440462
    Abstract: The invention relates to the use of a silanised hydroxypropylmethylcellulose (HPMC) or silanised hydroxyethylcellulose (HEC) hydrogel, self-crosslinking as a function of pH, for the three-dimensional ex vivo culture of chondrocytes.
    Type: Grant
    Filed: May 24, 2010
    Date of Patent: May 14, 2013
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes
    Inventors: Pierre Weiss, Jérôme Guicheux, Guy Daculsi, Gaël Grimandi, Claire Vinatier
  • Publication number: 20130102521
    Abstract: The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to auto oxidation and superior oxygen carrying characteristics.
    Type: Application
    Filed: December 14, 2012
    Publication date: April 25, 2013
    Applicant: SANGART, INC.
    Inventor: Sangart, Inc.
  • Publication number: 20130101564
    Abstract: Dermis tissue cell aggregation, which comprises isolated dermis tissue cells with biological activity, is provided. The isolated dermis tissue cells are preserved in a mixed solution consisting of an isotonic saline solution for medical use, an anticoagulant, a nutrient for cells and a cell growth promoter, and a non-fluidity dermis tissue cell aggregation with adhesion is formed after several processes. A method for preparing the dermis tissue cell aggregation and the use thereof in preparing medicines for repairing scars are provided.
    Type: Application
    Filed: June 30, 2010
    Publication date: April 25, 2013
    Inventor: Jinxi Chen
  • Patent number: 8426131
    Abstract: Investigation on the frequency of FLT3/ITD found in various blood cancers has revealed that the frequency is high in acute myeloblastic leukemia in particular. Studies on the effects of FLT3/ITD in the blood cell lines revealed that the tyrosine residues in FLT3/ITD is constitutively phosphorylated in these cell lines and that blood cells into which FLT3/ITD is introduced show IL-3 independent proliferation. Moreover, the blood cells into which FLT3/ITD is introduced are found to be capable of forming tumors and inhibit cell differentiation. The inventors have found that it is possible to screen for pharmaceutical compounds against tumors by using inhibition of these FLT3/ITD functions as an index.
    Type: Grant
    Filed: November 12, 2010
    Date of Patent: April 23, 2013
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Hitoshi Kiyoi, Tomoki Naoe, Masayuki Towatari, Toshio Kitamura
  • Publication number: 20130089912
    Abstract: A method of screening an organic salt for potential toxicity if used as a stabilizing agent for live cells or viruses, the method comprising: (a) providing a composition of unilamellar vesicles; then (b) contacting an organic salt to the unilamellar vesicles; and then (c) detecting a change in at least one thermal parameter of the unilamellar vesicles caused by the organic salt at said known concentration. A change in the at least one thermal parameter indicates the organic salt is potentially toxic for use as a stabilizing agent for live cells or viruses. Compositions of organic salts identified by such methods, along with methods of using the same in stabilizing live cells or viruses, are also described.
    Type: Application
    Filed: October 5, 2012
    Publication date: April 11, 2013
    Inventors: Gloria Elliott, Douglas R. MacFarlane
  • Publication number: 20130065301
    Abstract: An auto-nucleating device includes a tube containing a crystalline cholesterol matrix. The ends of the tube are closed by a membrane impermeable to the cholesterol but permeable to liquids contained in a cryopreservation vessel. The auto-nucleating device provides a site for ice nucleation during freezing of the liquid within the vessel. The cryopreservation vessel can be a flexible vial having a closed port adapted to be pierced by a needle, and an opposite end that is initially open to receive the liquid. Another vessel includes an adaptor mounted to liquid container with a tubular branch closed by a needle septum and another tubular branch provided with a barbed fitting for engaging a flexible tube that terminates in a needle septum. Alternatively, the vessel includes an inlet and vent branch at the top of the container and an outlet septum at a bottom opening.
    Type: Application
    Filed: July 16, 2012
    Publication date: March 14, 2013
    Inventors: Erik John Woods, John K. Critser
  • Publication number: 20130065302
    Abstract: Human umbilical cord lining stem cells that are capable of differentiating into cells of the mesodermal lineage and ectodermal lineage are described, as well as methods of isolating, expanding, culturing, and cryopreserving such cells.
    Type: Application
    Filed: November 2, 2012
    Publication date: March 14, 2013
    Applicant: DAVINCI BIOSCIENCES LLC
    Inventor: DAVINCI BIOSCIENCES LLC
  • Publication number: 20130059285
    Abstract: It is provided an improved aqueous solution for the preservation of tissues and organs comprising carvedilol, tacrolimus, and trimetazidine. A synergistic effect is observed for this preservation solution which is particularly effective in marginal organs, such as steatotic livers.
    Type: Application
    Filed: May 18, 2009
    Publication date: March 7, 2013
    Applicants: UNIVERSIDAD DE BARCELONA, CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS, INSTITUT D'INVESTIGACIONS BIOMÉDIQUES AUGUST PI I SUNYER
    Inventors: Carmen Peralta Uroz, Ismail Ben Mosbah, Ramon Bartrons Bach
  • Publication number: 20130059380
    Abstract: The present invention provides compositions (i.e., preservation solutions) for preserving biologies comprising at least one membrane penetrable sugar, at least one membrane impenetrable sugar, at least one anti-microbial agent, at least one anti-oxidant, adenosine, albumin, a salt, a buffer, and a chelating agent, and to methods of using such preservation solutions to preserve biologies.
    Type: Application
    Filed: February 16, 2011
    Publication date: March 7, 2013
    Applicant: HeMemics Biotechnologies, Inc.
    Inventors: David Ho, Stephen Bruttig
  • Publication number: 20130059381
    Abstract: The invention provides a solution for non-programmed cell cryopreservation, which comprises 1.0-28 w/v % of cell membrane protectant, 1.0-18 w/v % of permeable intracellular protectant, 3.0-28 w/v % of cell sedimentation stabilizer, and the balance of solvent. The cell cryopreservation solution provided by the invention is good for protecting cells. After the cryopreservation solution is added to cells, the cells can be cryopreserved in a refrigerator of ?80 DEG C. directly without complicated programmed cryopreservation, thus, the time for cell cryopreservation is shortened greatly and the efficiency of cryopreservation is improved. Therefore, the cryopreservation solution is suitable for cryopreserving a large number of cells. The recovery rate of the cells cryopreserved is high, the growth and differentiation of the recovered cells is normal. The components of the cryopreservation solution are stable, thus the cryopreservation solution can be preserved with good property for a long time.
    Type: Application
    Filed: July 31, 2010
    Publication date: March 7, 2013
    Inventors: Xiaoying Mo, Dunwu Zheng, Baoli Wei, Jiahui Chen, Qingyan Luo
  • Publication number: 20130052211
    Abstract: Disclosed are compositions containing isolated monocyte-derived mature dendritic cells loaded with OFA/iLRP, or a fragment thereof that selectively stimulates T cytotoxic lymphocytes, and a carrier, vaccine compositions containing effective dosage amounts of the dendritic cells, methods of making the vaccines, and methods of cancer treatment or therapy that entail administration of the vaccines to cancer patients.
    Type: Application
    Filed: July 9, 2010
    Publication date: February 28, 2013
    Applicant: SOUTH ALABAMA MEDICAL SCIENCE
    Inventors: Adel L. Barsoum, Suzanne Rohrer, Cindy C. Segers, Kurt M. Coggin
  • Publication number: 20130052168
    Abstract: A kit is disclosed that includes a first component comprising alginate, wherein the first component is comprised in a first sterile vial, and a second component comprising cells comprising keratinocytes or fibroblasts, or mixtures thereof, that secrete one or more biologically active molecules selected from the group consisting of GM-CSF, VEGF, KGF, bFGF, TGF?, angiopoietin, EGF, IL-I?, IL-6, IL-8, TGF?, and TNF?, wherein the cells are allogeneic and mitotically inactive, a buffered solution, and human serum albumin or a cryoprotectant, wherein the second component is comprised in a second sterile vial.
    Type: Application
    Filed: October 24, 2012
    Publication date: February 28, 2013
    Applicant: HEALTHPOINT INTERNATIONAL, LLC
    Inventor: Healthpoint International, LLC
  • Publication number: 20130052730
    Abstract: Methods and systems for cryogenic preservation of cells.
    Type: Application
    Filed: August 23, 2012
    Publication date: February 28, 2013
    Applicant: BIOCISION, LLC
    Inventor: Brian Schryver
  • Publication number: 20130052169
    Abstract: A stem cell bank is disclosed which stores stem cells collected from individuals throughout their entire life. The stem cell bank stores stem cells of various types, which are obtained from a plurality of sources from a single individual. Also provided are methods of personalized medicine that utilizes cells stored in a bank and compositions of stem cells for the treatment of various types of diseases.
    Type: Application
    Filed: May 5, 2011
    Publication date: February 28, 2013
    Applicant: STEM CELL MEDICINE LTD.
    Inventor: Ehud Marom
  • Patent number: 8377689
    Abstract: The invention relates to the discovery of a selective cell surface marker that permits the selection of a unique subset of pancreatic stem cells having a high propensity to differentiate into insulin-producing cells or into insulin-producing cell aggregates.
    Type: Grant
    Filed: September 24, 2010
    Date of Patent: February 19, 2013
    Assignee: ReNeuron, Inc.
    Inventors: Wen-Ghih Tsang, Yanping Wang, Jinghua Tang
  • Patent number: 8367344
    Abstract: Disclosed in a method of detecting cancer using IL-27 receptors. IL27R is a cytokine receptor identified as a novel oncogene from an acute myeloid leukemia patient. It induces cancer-like properties when expressed in cells and can activate a protein that causes various myeloid cell disorders. The data show cytokine receptors play unappreciated roles in mediating activation of signaling pathways in circulatory system cancers. Also method of screening for novel oncogenes using a functional, approach is disclosed using cytokine-dependent cells to screen for transforming events.
    Type: Grant
    Filed: April 16, 2010
    Date of Patent: February 5, 2013
    Assignee: University of South Florida
    Inventor: Gary Willard Reuther
  • Publication number: 20130023049
    Abstract: Viable progenitor cells are extracted from frozen umbilical cord tissue. In embodiments, the umbilical cord tissue is a blood vessel bearing perivascular Wharton's jelly, and the extracted progenitor cells are HUCPVCs.
    Type: Application
    Filed: September 28, 2012
    Publication date: January 24, 2013
    Inventors: Jane E. ENNIS, Rahul SARUGASER, John E. DAVIES
  • Publication number: 20130022581
    Abstract: The present invention provides placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. The invention also provides methods of differentiating the placental stem cells. The invention further provides methods of using the placental stem cells in assays and for transplanting.
    Type: Application
    Filed: May 24, 2012
    Publication date: January 24, 2013
    Inventors: James EDINGER, Qian Ye, Jai-Lun Wang, Robert J. Hariri
  • Publication number: 20130012404
    Abstract: It is intended to provide a method for culturing a novel cancer tissue-derived cell mass or a novel aggregated cancer cell mass that can reflect the behavior of cancer cells accurately in vivo. First, a cancer tissue-derived cell mass or an aggregated cancer cell mass is prepared from an individual. The novel cancer tissue-derived cell mass or the novel aggregated cancer cell mass is cultured, and the properties are evaluated using the cultured cell mass. Examples of the evaluation of properties include the evaluation of genes and the evaluation of culture conditions. In addition, the cancer tissue-derived cell mass or the aggregated cancer cell mass can be stored. It is possible to establish an optimal therapeutic method for an individual efficiently by linking the clinical information or the genetic information on the individual to the stored cancer tissue-derived cell mass or the stored aggregated cancer cell mass.
    Type: Application
    Filed: January 19, 2011
    Publication date: January 10, 2013
    Inventor: Masahiro Inoue
  • Patent number: 8349558
    Abstract: The present invention relates to a method for identifying the preferential target antigens of antitumoural T-cells of a tumour patient, comprising: a) providing T-cells from the blood of at least one tumour patient, b) providing dendritic cell (DCs) and/or B-lymphocytes (BLCs) that are autologous for said tumour patient, wherein said DCs and BLCs were transfected beforehand with a selection of mRNAs encoding for T-cell-immunogenic tumour-associated antigens (TAA), and express these, c) contacting said T-cells with the DCs and/or BLCs, d) identifying of those T-cells that recognize antigens of the DCs and/or BLCs, and e) identifying of the preferential target antigens of antitumoural T-cells of the at least one tumour patient on the basis of the T-cells that recognize antigens of the DCs and/or BLCs. The method can furthermore comprise the expansion of the T-cells that recognize the antigens of the DCs and/or BLCs.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: January 8, 2013
    Assignee: Johannes Gutenberg-Universitat Mainz
    Inventors: Martina Fatho, Emmanuelle Wesarg, Volker Lennerz, Pierre Van Der Bruggen, Thomas Wölfel, Serena Debo
  • Patent number: 8349807
    Abstract: It is an object of the present invention to a method whereby a humoral immune response is induced more efficiently in producing an antibody against an antigen protein by gene immunization. A fusion gene composed of a gene encoding the full-length of a part of the antigen protein or a gene encoding a chaperonin subunit or a chaperonin subunit linkage linked thereto is administered to express the fusion gene in the animal, thereby inducing a humoral immune response to an antigen protein by administering. An example of the chaperonin includes Escherichia coli GroEL. There is also provided with a composition for immunization, a method for producing an antibody, a method for producing a hybridoma, and a method for producing a monoclonal antibody.
    Type: Grant
    Filed: October 14, 2005
    Date of Patent: January 8, 2013
    Assignees: Joe Chiba, Sekisui Chemical Co., Ltd.
    Inventors: Joe Chiba, Jun-ichi Hata, Naoki Nishiguchi, Masahiro Furutani
  • Publication number: 20130004468
    Abstract: The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.
    Type: Application
    Filed: July 2, 2012
    Publication date: January 3, 2013
    Applicant: Cellerant Therapeutics, Inc.
    Inventors: Timothy C. Fong, Adrianus Geertrudis Wilhelmus Domen, Julie Lynne Christensen
  • Publication number: 20130005036
    Abstract: The present application discloses a method of obtaining multi-lineage stem cells or progenitor cells by allowing a sample of cells to settle in a container; transferring supernatant from the container to another container; and eventually isolating a colony from the supernatant after several transfer/settle processes and expanding further, and optionally freezing the cells thus obtained.
    Type: Application
    Filed: December 30, 2011
    Publication date: January 3, 2013
    Inventor: Sun Uk Song
  • Publication number: 20130004936
    Abstract: The present invention discloses a supercooling promoting agent comprising a tannin for producing practical water which does not freeze. As the tannin, a hydrolyzable tannin such as 2,3,6-tri-O-galloyl-?,?-D-hamamelose, 1,2,6-tri-O-galloyl-?-D-glucose, and a vitrification liquid, each of which contains the supercooling promoting agent are useful as a solution or the like for storing a biological material at low temperature.
    Type: Application
    Filed: March 3, 2011
    Publication date: January 3, 2013
    Applicant: National University Corporation Hokkaido Universit
    Inventors: Seizo Fujikawa, Yukiharu Fukiharu, Keita Arakawa, Hiroshi Nishioka
  • Patent number: 8338173
    Abstract: Cytotoxic ?? T cells form an essential component in immunity to infections and tumors, and are also implicated in host defense against these challenges. The present disclosure demonstrates the ability of activated ?? T cells to cross-present exogenous antigens to CD8+ ?? T cells, a process previously thought to be mediated best by dendritic cells. In particular, the present disclosure provides a method for cross-presentation of antigen derived from tumor cell or microbial organisms such as viruses, bacteria, yeasts, parasites, and the like, or from cells infected with such organisms, to a CD8+ ?? T cell. Still further, the present disclosure provides a method for treatment of a tumor or a chronic or recurrent infectious disease, comprising delivering an antigen-presenting autologous ?? T cell population above into a patient requiring such treatment. Still yet further, a method is described for preparing a peptide-specific effector T cell.
    Type: Grant
    Filed: November 14, 2008
    Date of Patent: December 25, 2012
    Assignee: University College Cardiff Consultants Limited
    Inventors: Bernhard Moser, Marlene Brandes Kuchen
  • Publication number: 20120308987
    Abstract: The present invention provides compositions useful for biomolecule storage comprising a water soluble inorganic compound, a stabilizer, or a combination thereof. The present invention also provides methods of using the compositions of the invention to store biomolecules in the dry state and in solution, as well as sample carriers and kits comprising compositions of the invention.
    Type: Application
    Filed: August 20, 2012
    Publication date: December 6, 2012
    Applicant: GenVault Corporation
    Inventors: Michael HOGAN, Michael SAGHBINI, Chunnian SHI, David WONG
  • Publication number: 20120301866
    Abstract: The invention relates to a liquid formulation including a liquid solution and at least one gas selected from xenon, argon, hydrogen, H2S, helium, krypton, neon, radon or CO, said gas being dissolved in said liquid solution, for the use thereof as a preservative solution for preserving biological material, in particular cells, tissue and biological organs, in particular an organ selected from the heart, the kidney, the liver, the pancreas and the intestines. The gas is preferably argon.
    Type: Application
    Filed: January 21, 2011
    Publication date: November 29, 2012
    Applicant: L'Air Liquide, Société Anonyme pour I'Etude et I'Exploitation des Procédés Georges Claude
    Inventors: Andrew Martin, Marc Lemaire, Jan Pype, Chui Fung Chong
  • Publication number: 20120301959
    Abstract: The invention relates to a method for producing ready to use, antigen loaded or unloaded, cryoconserved mature dendritic cells especially for the production of a vaccine containing said dendritic cells, wherein immature dendritic cells are cultivated in the presence of suitable maturation stimuli and the mature dendritic cells thus obtained are frozen. The dendritic cells can be loaded with antigen before freezing. The invention also relates to a vaccine which can be obtained according to the inventive method and to a composition containing frozen, mature dendritic cells which are loaded with antigen.
    Type: Application
    Filed: May 24, 2012
    Publication date: November 29, 2012
    Applicant: ARGOS THERAPEUTICS, INC.
    Inventors: Gerold Schuler, Bearrice Schuler-Thurner
  • Publication number: 20120302575
    Abstract: The present disclosure is generally related to methods of preventing oxidative stress injury induced by renal is-chemia-reperfusion by a Folate-TEMPOL conjugate.
    Type: Application
    Filed: September 21, 2010
    Publication date: November 29, 2012
    Applicants: GEORGIA TECH RESEARCH CORPORATION, EMORY UNIVERSITY
    Inventors: W. Robert Taylor, Sarah F. Knight, Niren Murthy, Kousik Kundu
  • Publication number: 20120294836
    Abstract: The present invention provides processes for aseptically processing live mammalian cells in an aqueous medium to produce a cell suspension having a cell density of at least about 10 million cells/mL and cell viability of at least about 90%. These methods comprise a step of reducing the volume of the medium using a tangential flow filter (TFF) having a pore size of greater than 0.1 micron, during which step the trans-membrane pressure (TMP) is maintained at less than about 3 psi and the shear rate is maintained at less than about 4000 sec?1. The invention also provides a complete process for large scale manufacturing mammalian cells for use in a therapeutic composition, and scalable, fully disposable systems for carrying out the process, using readily available disposables and pumps.
    Type: Application
    Filed: July 19, 2012
    Publication date: November 22, 2012
    Applicant: LONZA WALKERSVILLE, INC.
    Inventors: Jonathan ROWLEY, Jacob PATTASSERIL, Ali MOHAMED
  • Publication number: 20120282591
    Abstract: Methods and compositions for resuscitating, storing, and preserving functional integrity of organs and tissues. Metabolic function is maintained by sustaining ATP levels, mitochondrial function, cardiomyocyte contractility, prevention of acidosis, inhibition of induction of apoptosis, maintaining ionontrophy and lusiotrophy by regulating calcium, sodium, potassium and chloride ions.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 8, 2012
    Applicants: United States Government as Represented by the Department of Veterans Affairs, President and Fellows of Harvard College
    Inventors: Hemant Thatte, Patrick Treanor, Shukri F. Khuri, Randa Khuri, Laki Rousou
  • Publication number: 20120276581
    Abstract: The claimed subject matter is based on the finding that it is possible to cryopreserve cancellous bone tissue with viable cells (after reconstitution by either thawing or rehydration), the viability after reconstitution being comparable to that of a fresh sample (without freezing) and of beneficial value for use in, for example, transplantation. Thus, provided is a method for cryopreserving a cancellous bone sample. The cryopreserved cancellous bone sample can be in dry form, for example, lyophilized. Also provided is a cryopreserved, in dry form, bone sample and the use of a cryopreserved bone sample; a method for identifying such cryopreserved cancellous bone tissue and uses thereof.
    Type: Application
    Filed: January 6, 2011
    Publication date: November 1, 2012
    Applicant: CORE DYNAMICS LTD.
    Inventors: Amir Arav, Victor Rzepakovsky, Isachar Norman, Olga Shneerson, Yehudit Natan
  • Publication number: 20120270203
    Abstract: The present invention relates to a composition for preserving cells, tissues and organs, comprising as an active ingredient indole and indazole compounds of formula (1), or a pharmaceutically acceptable salt or isomer thereof, which are effective for preventing injury of organs, isolated cell systems or tissues caused by cold storage, transplant operation or post-transplantation reperfusion; a preservation method; and a preparation method of the composition.
    Type: Application
    Filed: June 27, 2012
    Publication date: October 25, 2012
    Inventors: Soon Ha KIM, Hyoung Jin Kim, Chul Woong Chung, Heui Sul Park, Hyo Shin Kwak, Sung Ho Kim, Jin Gu Park
  • Publication number: 20120270293
    Abstract: A tissue sample preservation process and device for improving and standardizing tissue preservation procedure, including placing tissue specimens in a cold fixative, performing fixative penetration at a refrigerated temperature, and accelerating fixative penetration by ultrasound. Also disclosed is the application of ultrasound and temperature control in the dehydration, clearing, and impregnation steps.
    Type: Application
    Filed: December 1, 2010
    Publication date: October 25, 2012
    Inventor: Wei-Sing Chu